• LAST PRICE
    2.3900
  • TODAY'S CHANGE (%)
    Trending Up0.0400 (1.7021%)
  • Bid / Lots
    2.3100/ 1
  • Ask / Lots
    2.8000/ 7
  • Open / Previous Close
    2.4500 / 2.3500
  • Day Range
    Low 2.3100
    High 2.4500
  • 52 Week Range
    Low 2.2301
    High 70.5000
  • Volume
    32,983
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 2.35
TimeVolumeMYMD
09:32 ET103832.45
09:34 ET10672.4312
09:45 ET1002.44
09:54 ET2432.4
10:12 ET1002.4
10:33 ET24272.44
10:44 ET17352.435
10:50 ET2002.425
11:13 ET1062.4424
11:42 ET2502.43
11:49 ET5002.4292
11:54 ET1002.4299
12:16 ET32492.39
12:20 ET6952.4
12:41 ET15162.38
12:50 ET5002.37
02:04 ET2332.39
02:09 ET1112.3769
02:27 ET1672.3999
02:36 ET9962.4
02:49 ET1092.37
02:54 ET1432.4
03:30 ET2002.35
03:36 ET7442.39
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMYMD
Mymd Pharmaceuticals Inc
4.9M
-0.4x
---
United StatesBTAX
Biostax Corp
4.8M
-3.0x
---
United StatesARTL
Artelo Biosciences Inc
4.7M
-0.5x
---
United StatesPKTX
ProtoKinetix Inc
5.1M
-16.0x
---
United StatesTHAR
Tharimmune Inc
5.1M
0.0x
---
United StatesGNPX
Genprex Inc
5.2M
-0.1x
---
As of 2024-03-28

Company Information

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).

Contact Information

Headquarters
855 N. Wolfe Street, Suite 601BALTIMORE, MD, United States 21205
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Joshua Silverman
President, Director, Chief Medical Officer
Chris Chapman
Interim Chief Financial Officer
Ian Rhodes
Executive Vice President - Operations, General Counsel, Chief Legal Officer
Paul Rivard
Chief Scientific Officer
Adam Kaplin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.9M
Revenue (TTM)
$0.00
Shares Outstanding
2.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.30
EPS
$-5.53
Book Value
$11.17
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.